Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2016 Mar 22

PMID 26999211

Citations 264

Authors

Vita Golubovskaya

Lijun Wu

Affiliations

Soon will be listed here.

Abstract

This review is focused on different subsets of T cells: CD4 and CD8, memory and effector functions, and their role in CAR-T therapy--a cellular adoptive immunotherapy with T cells expressing chimeric antigen receptor. The CAR-T cells recognize tumor antigens and induce cytotoxic activities against tumor cells. Recently, differences in T cell functions and the role of memory and effector T cells were shown to be important in CAR-T cell immunotherapy. The CD4⁺ subsets (Th1, Th2, Th9, Th17, Th22, Treg, and Tfh) and CD8⁺ memory and effector subsets differ in extra-cellular (CD25, CD45RO, CD45RA, CCR-7, L-Selectin [CD62L], etc.); intracellular markers (FOXP3); epigenetic and genetic programs; and metabolic pathways (catabolic or anabolic); and these differences can be modulated to improve CAR-T therapy. In addition, CD4⁺ Treg cells suppress the efficacy of CAR-T cell therapy, and different approaches to overcome this suppression are discussed in this review. Thus, next-generation CAR-T immunotherapy can be improved, based on our knowledge of T cell subsets functions, differentiation, proliferation, and signaling pathways to generate more active CAR-T cells against tumors.

Citing Articles

Unlocking the Role of Treg Cells Immune Response and Infectious Risk Following CAR T-Cell Therapy in Patients with Cancer.

Dicharry D, Malek A Int J Mol Sci. 2025; 26(4).

PMID: 40004068 PMC: 11854923. DOI: 10.3390/ijms26041602.

Wang H, Li Y, Li H, Yan X, Jiang Z, Feng L J Orthop Translat. 2025; 51:82-93.

PMID: 39991456 PMC: 11847249. DOI: 10.1016/j.jot.2024.12.004.

Role of CD4 T cells in cancer immunity: a single-cell sequencing exploration of tumor microenvironment.

An Q, Duan L, Wang Y, Wang F, Liu X, Liu C J Transl Med. 2025; 23(1):179.

PMID: 39953548 PMC: 11829416. DOI: 10.1186/s12967-025-06167-1.

Immune Cell Interactions and Immune Checkpoints in the Tumor Microenvironment of Gastric Cancer.

Cozac-Szoke A, Cozac D, Negovan A, Tinca A, Vilaia A, Cocuz I Int J Mol Sci. 2025; 26(3).

PMID: 39940924 PMC: 11818890. DOI: 10.3390/ijms26031156.

Titanium nanotubes modulate immunophenotyping and cytokine secretion of T cells via IL-17A: a bioinformatic analysis and experimental validation.

Yin J, Liao Y, Liu S, Che B, Zhu H, Yang B Front Immunol. 2025; 15():1381158.

PMID: 39840051 PMC: 11747796. DOI: 10.3389/fimmu.2024.1381158.

References

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

Lanitis E, Poussin M, Klattenhoff A, Song D, Sandaltzopoulos R, June C . Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2014; 1(1):43-53. PMC: 3881605. DOI: 10.1158/2326-6066.CIR-13-0008. View

Rosenblum M, Way S, Abbas A . Regulatory T cell memory. Nat Rev Immunol. 2015; 16(2):90-101. PMC: 5113825. DOI: 10.1038/nri.2015.1. View

Pearce E, Poffenberger M, Chang C, Jones R . Fueling immunity: insights into metabolism and lymphocyte function. Science. 2013; 342(6155):1242454. PMC: 4486656. DOI: 10.1126/science.1242454. View

John L, Kershaw M, Darcy P . Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013; 2(10):e26286. PMC: 3862687. DOI: 10.4161/onci.26286. View

Sukumar M, Liu J, Mehta G, Patel S, Roychoudhuri R, Crompton J . Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab. 2015; 23(1):63-76. PMC: 4747432. DOI: 10.1016/j.cmet.2015.11.002. View

Gargett T, Brown M . Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2. Cytotherapy. 2015; 17(4):487-95. DOI: 10.1016/j.jcyt.2014.12.002. View

Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo N . Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol Immunother. 2012; 62(4):727-36. PMC: 6354242. DOI: 10.1007/s00262-012-1378-2. View

Chmielewski M, Abken H . CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012; 61(8):1269-77. PMC: 11029721. DOI: 10.1007/s00262-012-1202-z. View

10.

Shedlock D, Shen H . Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003; 300(5617):337-9. DOI: 10.1126/science.1082305. View

11.

Lamers C, van Steenbergen-Langeveld S, van Brakel M, Groot-van Ruijven C, van Elzakker P, van Krimpen B . T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum Gene Ther Methods. 2014; 25(6):345-57. PMC: 4268575. DOI: 10.1089/hgtb.2014.051. View

12.

Kakarla S, Gottschalk S . CAR T cells for solid tumors: armed and ready to go?. Cancer J. 2014; 20(2):151-5. PMC: 4050065. DOI: 10.1097/PPO.0000000000000032. View

13.

Gross G, Waks T, Eshhar Z . Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989; 86(24):10024-8. PMC: 298636. DOI: 10.1073/pnas.86.24.10024. View

14.

Berger C, Jensen M, Lansdorp P, Gough M, Elliott C, Riddell S . Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2007; 118(1):294-305. PMC: 2104476. DOI: 10.1172/JCI32103. View

15.

Chmielewski M, Kopecky C, Hombach A, Abken H . IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011; 71(17):5697-706. DOI: 10.1158/0008-5472.CAN-11-0103. View

16.

Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M . Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS One. 2015; 10(6):e0130518. PMC: 4482147. DOI: 10.1371/journal.pone.0130518. View

17.

Abken H . Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy. 2015; 7(5):535-44. DOI: 10.2217/imt.15.15. View

18.

Gross G, Eshhar Z . Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy. Annu Rev Pharmacol Toxicol. 2016; 56:59-83. DOI: 10.1146/annurev-pharmtox-010814-124844. View

19.

Moeller M, Haynes N, Kershaw M, Jackson J, Teng M, Street S . Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood. 2005; 106(9):2995-3003. DOI: 10.1182/blood-2004-12-4906. View

20.

Liadi I, Singh H, Romain G, Rey-Villamizar N, Merouane A, Adolacion J . Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. Cancer Immunol Res. 2015; 3(5):473-82. PMC: 4421910. DOI: 10.1158/2326-6066.CIR-14-0195. View